Cargando…

Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin-based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials

Predicting tumor response prior to starting anti-epidermal growth factor receptor (EGFR) antibody therapy would benefit patients with advanced/metastatic colorectal cancer (mCRC). The present study investigated the association between efficacy of cetuximab treatment and gene polymorphisms of fragmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maeda, Hiromichi, Hazama, Shoichi, Iwamoto, Shigeyoshi, Oba, Koji, Tsunedomi, Ryouichi, Okayama, Naoko, Suehiro, Yutaka, Yamasaki, Takahiro, Nakagami, Yuki, Suzuki, Nobuaki, Nagano, Hiroaki, Sakamoto, Junichi, Mishima, Hideyuki, Nagata, Naoki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781779/ https://www.ncbi.nlm.nih.gov/pubmed/31611963 http://dx.doi.org/10.3892/ol.2019.10787

Ejemplares similares

Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer
por: Iwamoto, Shigeyoshi, et al.
Publicado: (2018)

Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations
por: Maeda, Hiromichi, et al.
Publicado: (2014)

A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes
por: TSUNEDOMI, RYOUICHI, et al.
Publicado: (2014)

Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray
por: Tsunedomi, Ryouichi, et al.
Publicado: (2017)

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
por: Soda, Hitoshi, et al.
Publicado: (2015)

Novel Biomarkers for Personalized Cancer Immunotherapy
por: Shindo, Yoshitaro, et al.
Publicado: (2019)

Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer
por: Inoue, Yuka, et al.
Publicado: (2017)

Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer
por: Kuwahara, Taichi, et al.
Publicado: (2019)

Correction: Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer
por: Kuwahara, Taichi, et al.
Publicado: (2019)

Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
por: Ishibashi, Keiichiro, et al.
Publicado: (2021)

Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs
por: Hashimoto, Noriaki, et al.
Publicado: (2014)

Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
por: Nakamura, Masato, et al.
Publicado: (2016)

Hedgehog Signals Mediate Anti-Cancer Drug Resistance in Three-Dimensional Primary Colorectal Cancer Organoid Culture
por: Usui, Tatsuya, et al.
Publicado: (2018)

Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity
por: Kanesada, Kou, et al.
Publicado: (2022)

Establishment of a Novel Model for Anticancer Drug Resistance in Three-Dimensional Primary Culture of Tumor Microenvironment
por: Usui, Tatsuya, et al.
Publicado: (2016)

Prediction of the efficacy of immunotherapy by measuring the integrity of cell‐free DNA in plasma in colorectal cancer
por: Kitahara, Masahiro, et al.
Publicado: (2016)

Metastatic ability and the epithelial‐mesenchymal transition in induced cancer stem‐like hepatoma cells
por: Nishiyama, Mitsuo, et al.
Publicado: (2018)

MicroRNA-6826 and −6875 in plasma are valuable non-invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer
por: Kijima, Taiki, et al.
Publicado: (2017)

Cathepsin B is highly expressed in pancreatic cancer stem-like cells and is associated with patients' surgical outcomes
por: Fujimoto, Takuya, et al.
Publicado: (2021)

Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy
por: Kono, Toru, et al.
Publicado: (2013)

FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study)
por: Mishima, Hideyuki, et al.
Publicado: (2012)

Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)
por: Kotake, Masanori, et al.
Publicado: (2017)

CD4 and FOXP3 as predictive markers for the recurrence of T3/T4a stage II colorectal cancer: applying a novel discrete Bayes decision rule
por: Nakagami, Yuki, et al.
Publicado: (2022)

High secreted protein acidic and rich in cysteine expression in peritumoral fibroblasts predicts better prognosis in patients with resectable gastric cancer
por: Nakajima, Masao, et al.
Publicado: (2018)

Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study
por: Tezuka, Tohru, et al.
Publicado: (2013)

Pancreatic Cancer Stem-Like Cells With High Calreticulin Expression Associated With Immune Surveillance
por: Fujiwara, Yasuhiro, et al.
Publicado: (2021)

A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome
por: Hazama, Shoichi, et al.
Publicado: (2014)

Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer
por: Munemoto, Yoshinori, et al.
Publicado: (2015)

miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer
por: Shindo, Yoshitaro, et al.
Publicado: (2017)

Elevated expression of RAB3B plays important roles in chemoresistance and metastatic potential of hepatoma cells
por: Tsunedomi, Ryouichi, et al.
Publicado: (2022)

A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)
por: Hazama, Shoichi, et al.
Publicado: (2014)

Relationship Between Cytokine Gene Polymorphisms and Risk of Postoperative Pneumonia with Esophageal Cancer
por: Sakamoto, Kazuhiko, et al.
Publicado: (2014)

Fyn-Mediated Paxillin Tyrosine 31 Phosphorylation Regulates Migration and Invasion of Breast Cancer Cells
por: Zhang, Ying, et al.
Publicado: (2023)

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
por: Narvi, Elli, et al.
Publicado: (2018)

Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma
por: Yamamoto, Yoshiaki, et al.
Publicado: (2018)

Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancer
por: Yamada, Kensuke, et al.
Publicado: (2021)

Determining the protective characteristics and risk factors for the development of anastomotic leakage after low anterior resection for rectal cancer
por: Suzuki, Nobuaki, et al.
Publicado: (2020)

Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer
por: Shindo, Yoshitaro, et al.
Publicado: (2014)

A stem cell medium containing neural stimulating factor induces a pancreatic cancer stem-like cell-enriched population
por: WATANABE, YUSAKU, et al.
Publicado: (2014)

Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer
por: Santoro, Valeria, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_40btas43o7j0mm0rkr1edg0e1e